Trametinib dimethyl sulfoxide

  • Part D specialty tier in 80% of formularies (2026Q3)
  • Mekinist

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Trametinib dimethyl sulfoxide: storage and handling

Refrigerate
Yes, as the label states
Label statement
Store refrigerated at 2°C to 8°C (36°F to 46°F).
Freezing
Do not freeze
Label statement
After reconstitution, store in the original bottle below 25°C (77°F) and do not freeze.
Room temperature
at or below 30°C (86°F)
Label statement
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
Room temperature
at or below 25°C (77°F)
Label statement
Storage of MEKINIST oral solution Store the amber bottle of MEKINIST oral solution at room temperature below 77°F (25°C).
Room temperature
at or below 25°C (77°F)
Label statement
MEKINIST tablets: Store MEKINIST tablets at room temperature between 68°F to 77°F (20°C to 25°C).
Room temperature
at or below 25°C (77°F)
Label statement
MEKINIST for oral solution: Store MEKINIST for oral solution in the original amber bottle at room temperature below 77°F (25°C).
Back into the refrigerator
Not addressed
Light
Protect from light
Label statement
Store in the original carton to protect from light and moisture.
Shaking
Not addressed

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

Within the label's stated room-temperature allowance (at up to 30°C (86°F)). Follow the label's instructions for what to do next.

Entered: 1 day at up to 77°F (25°C).

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
Discard any unused solution 35 days after reconstitution.
Do not use MEKINIST oral solution after the expiration or “discard after” date written or printed on the label by the pharmacist.
Throw away unused MEKINIST for oral solution after the expiration or “discard after” date written on the amber bottle label.

If anything else happened to the product, or you are unsure, Contact the manufacturer at 1-888-669-6682 (the number printed on the label) about this product.

Where the label prints this number
You may also report side effects to Novartis Pharmaceuticals Corporation at 1-888-669-6682.
All storage statements on the label (14)
  • Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
  • Store refrigerated at 2°C to 8°C (36°F to 46°F).
  • Store in the original carton to protect from light and moisture.
  • After reconstitution, store in the original bottle below 25°C (77°F) and do not freeze.
  • Discard any unused solution 35 days after reconstitution.
  • Storage of MEKINIST oral solution Store the amber bottle of MEKINIST oral solution at room temperature below 77°F (25°C).
  • Do not freeze MEKINIST oral solution.
  • Store the amber bottle of MEKINIST oral solution upright with the cap tightly closed.
  • Do not use MEKINIST oral solution after the expiration or “discard after” date written or printed on the label by the pharmacist.
  • Storage of oral syringe Store the oral syringe with the MEKINIST oral solution.
  • MEKINIST tablets: Store MEKINIST tablets at room temperature between 68°F to 77°F (20°C to 25°C).
  • MEKINIST for oral solution: Store MEKINIST for oral solution in the original amber bottle at room temperature below 77°F (25°C).
  • Do not freeze.
  • Throw away unused MEKINIST for oral solution after the expiration or “discard after” date written on the amber bottle label.

FDA label version 35, effective May 7, 2026. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

100%of plans list it
98%of those: prior authorization
0%step therapy
77%quantity limit
97%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.